BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-533. [PMID: 26694080 DOI: 10.1111/apt.13497] [Cited by in Crossref: 310] [Cited by in F6Publishing: 288] [Article Influence: 44.3] [Reference Citation Analysis]
Number Citing Articles
1 Hu Y, Zhu Y, Lu NH. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Front Cell Infect Microbiol 2017;7:168. [PMID: 28529929 DOI: 10.3389/fcimb.2017.00168] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
2 Arslan N, Yılmaz Ö, Demiray-Gürbüz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol 2017; 23(16): 2854-2869 [PMID: 28522904 DOI: 10.3748/wjg.v23.i16.2854] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
3 Yun J, Wu Z, Qi G, Han T, Zhang D. The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol 2021;15:149-57. [PMID: 32960107 DOI: 10.1080/17474124.2021.1826306] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Marrero Rolon R, Cunningham SA, Mandrekar JN, Polo ET, Patel R. Clinical Evaluation of a Real-Time PCR Assay for Simultaneous Detection of Helicobacter pylori and Genotypic Markers of Clarithromycin Resistance Directly from Stool. J Clin Microbiol 2021;59:e03040-20. [PMID: 33536295 DOI: 10.1128/JCM.03040-20] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Sue S, Kuwashima H, Iwata Y, Oka H, Arima I, Fukuchi T, Sanga K, Inokuchi Y, Ishii Y, Kanno M, Terada M, Amano H, Naito M, Iwase S, Okazaki H, Komatsu K, Kokawa A, Kawana I, Morimoto M, Saito T, Kunishi Y, Ikeda A, Takahashi D, Miwa H, Sasaki T, Tamura T, Kondo M, Shibata W, Maeda S. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication. Intern Med 2017;56:1277-85. [PMID: 28566587 DOI: 10.2169/internalmedicine.56.7833] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
6 Eed EM, Hawash YA, Khalifa AS, Alsharif KF, Alghamdi SA, Saber T, Ismail KA, Shehab-Eldeen SA. Molecular diagnosis of Helicobacter pylori antibiotic resistance in the Taif region, Saudi Arabia. Microbiol Immunol 2019;63:199-205. [PMID: 31045263 DOI: 10.1111/1348-0421.12686] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
7 Cosme A, Montes M, Ibarra B, Tamayo E, Alonso H, Mendarte U, Lizasoan J, Herreros-Villanueva M, Bujanda L. Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance. World J Gastroenterol 2017; 23(18): 3367-3373 [PMID: 28566898 DOI: 10.3748/wjg.v23.i18.3367] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
8 Kim SY, Lee SW, Choe JW, Jung SW, Hyun JJ, Jung YK, Koo JS, Yim HJ. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. Helicobacter 2017;22. [PMID: 28940815 DOI: 10.1111/hel.12441] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
9 Guo CG, Jiang F, Cheung KS, Li B, Ooi PH, Leung WK. Timing of prior exposure to antibiotics and failure of Helicobacter pylori eradication: a population-based study. J Antimicrob Chemother 2021:dkab415. [PMID: 34791274 DOI: 10.1093/jac/dkab415] [Reference Citation Analysis]
10 Gingold-Belfer R, Niv Y, Schmilovitz-Weiss H, Levi Z, Boltin D. Susceptibility-guided versus empirical treatment for Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021. [PMID: 34114673 DOI: 10.1111/jgh.15575] [Reference Citation Analysis]
11 Gatta L, Scarpignato C, Fiorini G, Belsey J, Saracino IM, Ricci C, Vaira D. Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther 2018;47:1261-9. [DOI: 10.1111/apt.14597] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
12 Lee S, Sneed GT, Brown JN. Treatment of Helicobacter pylori with nitazoxanide-containing regimens: a systematic review. Infect Dis (Lond) 2020;52:381-90. [PMID: 31900002 DOI: 10.1080/23744235.2019.1708454] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Sasaki T, Saito R, Oyama M, Takeuchi T, Tanaka T, Natsume H, Tamura M, Arata Y, Hatanaka T. Galectin-2 Has Bactericidal Effects against Helicobacter pylori in a β-galactoside-Dependent Manner. Int J Mol Sci 2020;21:E2697. [PMID: 32295066 DOI: 10.3390/ijms21082697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Su DJ, Chang MH, Yang JC, Ni YH, Hsu HY, Wu JF. Fourteen-day sequential therapy is superior to 7-day triple therapy as first-line regimen for Helicobacter pylori infected children. J Formos Med Assoc 2021:S0929-6646(21)00106-6. [PMID: 33745813 DOI: 10.1016/j.jfma.2021.03.001] [Reference Citation Analysis]
15 Spósito L, Oda FB, Vieira JH, Carvalho FA, dos Santos Ramos MA, de Castro RC, Crevelin EJ, Crotti AEM, Santos AG, da Silva PB, Chorilli M, Bauab TM. In vitro and in vivo anti-Helicobacter pylori activity of Casearia sylvestris leaf derivatives. Journal of Ethnopharmacology 2019;233:1-12. [DOI: 10.1016/j.jep.2018.12.032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
16 Losurdo G, Giorgio F, Pricci M, Girardi B, Russo F, Riezzo G, Martulli M, Piazzolla M, Cocomazzi F, Abbruzzi F, Parente E, Paolillo R, Mileti A, Iannone A, Principi M, Ierardi E, Leo AD. Helicobacter pylori Primary and Secondary Genotypic Resistance to Clarithromycin and Levofloxacin Detection in Stools: A 4-Year Scenario in Southern Italy. Antibiotics (Basel) 2020;9:E723. [PMID: 33096925 DOI: 10.3390/antibiotics9100723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Kim SY, Chung JW. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics (Basel) 2020;9:E436. [PMID: 32717826 DOI: 10.3390/antibiotics9080436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Lucio-Sauceda DG, Urrutia-Baca VH, Gomez-Flores R, De La Garza-Ramos MA, Tamez-Guerra P, Orozco-Flores A. Antimicrobial and Anti-Biofilm Effect of an Electrolyzed Superoxidized Solution at Neutral-pH against Helicobacter pylori. Biomed Res Int 2019;2019:6154867. [PMID: 31930132 DOI: 10.1155/2019/6154867] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Mansour-Ghanaei F, Samadi A, Joukar F, Tirgar Fakheri H, Hassanipour S, Ashoobi MT, Soltanipour S, Alizadeh A, Rezamand G, Fathalipour M. Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of Helicobacter pylori: a randomized, double-blind clinical trial. EXCLI J 2019;18:644-52. [PMID: 31611747 DOI: 10.17179/excli2019-1613] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med 2019;8:E1498. [PMID: 31546909 DOI: 10.3390/jcm8091498] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
21 Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47:868-876. [PMID: 29430669 DOI: 10.1111/apt.14561] [Cited by in Crossref: 195] [Cited by in F6Publishing: 174] [Article Influence: 48.8] [Reference Citation Analysis]
22 Chang YL, Tung YC, Tu YK, Yeh HZ, Yang JC, Hsu PI, Kim SE, Wu MF, Liou WS, Shiu SI. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterol 2020;7:e000472. [PMID: 32883715 DOI: 10.1136/bmjgast-2020-000472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Katelaris PH, Katelaris AL. A prospective evaluation of levofloxacin-based triple therapy for refractory Helicobacter pylori infection in Australia: Levofloxacin triple therapy for refractory H. pylori. Intern Med J 2017;47:761-6. [DOI: 10.1111/imj.13432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
24 Beckman E, Saracino I, Fiorini G, Clark C, Slepnev V, Patel D, Gomez C, Ponaka R, Elagin V, Vaira D. A Novel Stool PCR Test for Helicobacter pylori May Predict Clarithromycin Resistance and Eradication of Infection at a High Rate. J Clin Microbiol. 2017;55:2400-2405. [PMID: 28515219 DOI: 10.1128/jcm.00506-17] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
25 Oikawa R, Watanabe Y, Miyamoto S, Sato Y, Ono S, Mabe K, Yamamoto H, Kato M, Itoh F. Enrichment of Helicobacter pylori mutant strains after eradication therapy analyzed by gastric wash-based quantitative pyrosequencing. Tumour Biol 2017;39:1010428317734865. [PMID: 28990461 DOI: 10.1177/1010428317734865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
26 Huang X, Sun X, Yu X, Qian H. WITHDRAWN: Efficacy and safety of Sijunzi decoction for peptic ulcers: a systematic review and meta-analysis. Journal of Traditional Chinese Medical Sciences 2018. [DOI: 10.1016/j.jtcms.2018.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Georgopoulos SD, Xirouchakis E, Martinez-Gonzales B, Zampeli E, Grivas E, Spiliadi C, Sotiropoulou M, Petraki K, Zografos K, Laoudi F. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. Eur J Intern Med. 2016;32:84-90. [PMID: 27134145 DOI: 10.1016/j.ejim.2016.04.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
28 Long X, Chen Q, Yu L, Liang X, Liu W, Lu H. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter 2018;23:e12485. [DOI: 10.1111/hel.12485] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
29 Rodríguez de Santiago E, Martín de Argila de Prados C, Marcos Prieto HM, Jorge Turrión MÃ, Barreiro Alonso E, Flores de Miguel A, de la Coba Ortiz C, Rodríguez Escaja C, Pérez Álvarez G, Ferre Aracil C, Aguilera Castro L, García García de Paredes A, Rodríguez Pérez A, Albillos Martínez A. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera ® ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study. Helicobacter 2017;22:e12423. [DOI: 10.1111/hel.12423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
30 Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter. 2019;24:e12570. [PMID: 30767339 DOI: 10.1111/hel.12570] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
31 Wojtyś MI, Jaźwiec R, Kazazić S, Leščić Ašler I, Knežević P, Aleksić Sabo V, Luić M, Jagusztyn-Krynicka EK, Bzowska A. A comprehensive method for determining cellular uptake of purine nucleoside phosphorylase and adenylosuccinate synthetase inhibitors by H. pylori. Appl Microbiol Biotechnol 2021;105:7949-67. [PMID: 34562116 DOI: 10.1007/s00253-021-11510-9] [Reference Citation Analysis]
32 Zhang XY, Shen WX, Chen CF, Sheng HH, Cheng H, Li J, Hu F, Lu DR, Gao HJ. Detection of the clarithromycin resistance of Helicobacter pylori in gastric mucosa by the amplification refractory mutation system combined with quantitative real-time PCR. Cancer Med. 2019;8:1633-1640. [PMID: 30864275 DOI: 10.1002/cam4.1986] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
33 Upala S, Sanguankeo A, Saleem SA, Jaruvongvanich V. Effects of Helicobacter pylori eradication on insulin resistance and metabolic parameters: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29:153-159. [PMID: 27832037 DOI: 10.1097/meg.0000000000000774] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
34 Gatta L, Scarpignato C. Editorial: Helicobacter pylori resistance and sequential therapy-authors’ reply. Aliment Pharmacol Ther 2018;48:96-7. [DOI: 10.1111/apt.14676] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
35 Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019;157:44-53. [PMID: 30998990 DOI: 10.1053/j.gastro.2019.04.011] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 30.0] [Reference Citation Analysis]
36 Iniyan AM, Kannan RR, Joseph FRS, Mary TRJ, Rajasekar M, Sumy PC, Rabel AM, Ramachandran D, Vincent SGP. In vivo safety evaluation of antibacterial silver chloride nanoparticles from Streptomyces exfoliatus ICN25 in zebrafish embryos. Microb Pathog 2017;112:76-82. [PMID: 28943148 DOI: 10.1016/j.micpath.2017.07.054] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
37 Kuo YT, Liou JM, El-Omar EM, Wu JY, Leow AHR, Goh KL, Das R, Lu H, Lin JT, Tu YK. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:707-715. [PMID: 28781119 DOI: 10.1016/s2468-1253(17)30219-4] [Cited by in Crossref: 96] [Cited by in F6Publishing: 39] [Article Influence: 19.2] [Reference Citation Analysis]
38 Singh SP, Ahuja V, Ghoshal UC, Makharia G, Dutta U, Zargar SA, Venkataraman J, Dutta AK, Mukhopadhyay AK, Singh A, Thapa BR, Vaiphei K, Sathiyasekaran M, Sahu MK, Rout N, Abraham P, Dalai PC, Rathi P, Sinha SK, Bhatia S, Patra S, Ghoshal U, Poddar U, Mouli VP, Kate V. Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology. Indian J Gastroenterol 2021. [PMID: 34219211 DOI: 10.1007/s12664-021-01186-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Hu Y, Zhu Y, Lu NH. Primary Antibiotic Resistance of Helicobacter pylori in China. Dig Dis Sci. 2017;62:1146-1154. [PMID: 28315035 DOI: 10.1007/s10620-017-4536-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
40 Rezaei S, Talebi Bezmin Abadi A, Mohabatti Mobarez A. Metronidazole-resistant Helicobacter pylori isolates without rdxA mutations obtained from Iranian dyspeptic patients. New Microbes New Infect 2020;34:100636. [PMID: 31993205 DOI: 10.1016/j.nmni.2019.100636] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
41 Ambay TM, Schick P, Grimm M, Sager M, Schneider F, Koziolek M, Siegmund W, Schindele F, Haas R, Weitschies W. Design and Optimization of a Novel Strategy for the Local Treatment of Helicobacter pylori Infections. J Pharm Sci 2021;110:1302-9. [PMID: 33253724 DOI: 10.1016/j.xphs.2020.11.021] [Reference Citation Analysis]
42 Nguyen CT, Davis KA, Nisly SA, Li J. Treatment of Helicobacter pylori in Special Patient Populations. Pharmacotherapy 2019;39:1012-22. [DOI: 10.1002/phar.2318] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
43 Wang X, Zhang D, Yin J, Nie S, Xie M. Recent developments in Hericium erinaceus polysaccharides: extraction, purification, structural characteristics and biological activities. Critical Reviews in Food Science and Nutrition 2019;59:S96-S115. [DOI: 10.1080/10408398.2018.1521370] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
44 Khashei R, Dara M, Bazargani A, Bagheri Lankarani K, Taghavi A, Moeini M, Dehghani B, Sohrabi M. High rate of A2142G point mutation associated with clarithromycin resistance among Iranian Helicobacter pylori clinical isolates. APMIS. 2016; Jun. 30 [Epub ahead of print]. [PMID: 27357065 DOI: 10.1111/apm.12567] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
45 Sharara AI. Confirmatory Testing for Eradication of Helicobacter pylori: Challenges and Opportunities. Clin Gastroenterol Hepatol 2021;19:232-4. [PMID: 32492481 DOI: 10.1016/j.cgh.2020.05.051] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Chang SH, Hsieh PL, Tsai GJ. Chitosan Inhibits Helicobacter pylori Growth and Urease Production and Prevents Its Infection of Human Gastric Carcinoma Cells. Mar Drugs 2020;18:E542. [PMID: 33138146 DOI: 10.3390/md18110542] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Raaf N, Amhis W, Saoula H, Abid A, Nakmouche M, Balamane A, Ali Arous N, Ouar-Korichi M, Vale FF, Bénéjat L, Mégraud F. Prevalence, antibiotic resistance, and MLST typing of Helicobacter pylori in Algiers, Algeria. Helicobacter 2017;22. [PMID: 29035009 DOI: 10.1111/hel.12446] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
48 Kim SJ, Chung JW, Woo HS, Kim SY, Kim JH, Kim YJ, Kim KO, Kwon KA, Park DK. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial. World J Gastroenterol 2019; 25(46): 6790-6798 [PMID: 31857780 DOI: 10.3748/wjg.v25.i46.6790] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
49 O'Connor A, O'Morain CA, Ford AC. Population screening and treatment of Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol. 2017;14:230-240. [PMID: 28053340 DOI: 10.1038/nrgastro.2016.195] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 15.4] [Reference Citation Analysis]
50 Chiu SF, Teng KW, Wang PC, Chung HY, Wang CJ, Cheng HC, Kao MC. Helicobacter pylori GmhB enzyme involved in ADP-heptose biosynthesis pathway is essential for lipopolysaccharide biosynthesis and bacterial virulence. Virulence 2021;12:1610-28. [PMID: 34125649 DOI: 10.1080/21505594.2021.1938449] [Reference Citation Analysis]
51 Bjorkman DJ, Steenblik M. Best Practice Recommendations for Diagnosis and Management of Helicobacter pylori-Synthesizing the Guidelines. Curr Treat Options Gastroenterol 2017;15:648-59. [PMID: 28932965 DOI: 10.1007/s11938-017-0157-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
52 Gao CP, Zhou Z, Wang JZ, Han SX, Li LP, Lu H. Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis. J Dig Dis. 2016;17:811-819. [PMID: 27977071 DOI: 10.1111/1751-2980.12432] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
53 Huang CC, Tsai KW, Tsai TJ, Hsu PI. Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy. Biomark Res 2017;5:23. [PMID: 28702193 DOI: 10.1186/s40364-017-0103-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
54 Matta AJ, Zambrano DC, Pazos AJ. Punctual mutations in 23S rRNA gene of clarithromycin-resistant Helicobacter pylori in Colombian populations. World J Gastroenterol 2018; 24(14): 1531-1539 [PMID: 29662291 DOI: 10.3748/wjg.v24.i14.1531] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
55 Malfertheiner P, Venerito M, Schulz C. Helicobacter pylori Infection: New Facts in Clinical Management. Curr Treat Options Gastroenterol. 2018;16:605-615. [PMID: 30415359 DOI: 10.1007/s11938-018-0209-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
56 Egli K, Wagner K, Keller PM, Risch L, Risch M, Bodmer T. Comparison of the Diagnostic Performance of qPCR, Sanger Sequencing, and Whole-Genome Sequencing in Determining Clarithromycin and Levofloxacin Resistance in Helicobacter pylori. Front Cell Infect Microbiol 2020;10:596371. [PMID: 33392106 DOI: 10.3389/fcimb.2020.596371] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
57 Nemidkanam V, Kato Y, Kubota T, Chaichanawongsaroj N. Ethyl acetate extract of Kaempferia parviflora inhibits Helicobacter pylori-associated mammalian cell inflammation by regulating proinflammatory cytokine expression and leukocyte chemotaxis. BMC Complement Med Ther 2020;20:124. [PMID: 32321502 DOI: 10.1186/s12906-020-02927-2] [Reference Citation Analysis]
58 Munteanu D, Etzion O, Ben-Yakov G, Halperin D, Eidelman L, Schwartz D, Novack V, Abufreha N, Krugliak P, Rozenthal A, Gaspar N, Moshkalo A, Dizingof V, Fich A. Efficacy and safety of sequential versus quadruple therapy as second-line treatment for helicobacter pylori infection-A randomized controlled trial. PLoS One. 2017;12:e0183302. [PMID: 28957341 DOI: 10.1371/journal.pone.0183302] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
59 Mannion A, Dzink-Fox J, Shen Z, Piazuelo MB, Wilson KT, Correa P, Peek RM Jr, Camargo MC, Fox JG. Helicobacter pylori Antimicrobial Resistance and Gene Variants in High- and Low-Gastric-Cancer-Risk Populations. J Clin Microbiol 2021;59:e03203-20. [PMID: 33692136 DOI: 10.1128/JCM.03203-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Palmitessa V, Monno R, Panarese A, Cuppone R, Burattini O, Marangi S, Curlo M, Fumarola L, Petrosillo A, Parisi A, Capozzi L, Bianco A, Lippolis A. Evaluation of Antibiotic Resistance of Helicobacter pylori Strains Isolated in Bari, Southern Italy, in 2017-2018 by Phenotypic and Genotyping Methods. Microb Drug Resist 2020;26:909-17. [PMID: 32101078 DOI: 10.1089/mdr.2019.0262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Leiman DA. Increasing Testing for Helicobacter pylori Infection to Improve Quality of Patient Care. Clin Gastroenterol Hepatol 2020;18:1028-9. [PMID: 31593768 DOI: 10.1016/j.cgh.2019.09.045] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Kocazeybek B, Sakli MK, Yuksel P, Demirci M, Caliskan R, Sarp TZ, Saribas S, Demiryas S, Kalayci F, Cakan H, Uysal HK, Gareayaghi N, Ergin S, Erzin YZ, Bal K, Tascı İ, Tokman HB. Comparison of new and classical point mutations associated with clarithromycin resistance in Helicobacter pylori strains isolated from dyspeptic patients and their effects on phenotypic clarithromycin resistance. J Med Microbiol 2019;68:566-73. [PMID: 30724729 DOI: 10.1099/jmm.0.000944] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
63 Qaria MA, Qumar S, Sepe LP, Ahmed N. Cholesterol glucosylation-based survival strategy in Helicobacter pylori. Helicobacter 2021;26:e12777. [PMID: 33368895 DOI: 10.1111/hel.12777] [Reference Citation Analysis]
64 Golkar T, Zieliński M, Berghuis AM. Look and Outlook on Enzyme-Mediated Macrolide Resistance. Front Microbiol 2018;9:1942. [PMID: 30177927 DOI: 10.3389/fmicb.2018.01942] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
65 Knezevic P, Aleksic Sabo V, Simin N, Lesjak M, Mimica-Dukic N. A colorimetric broth microdilution method for assessment of Helicobacter pylori sensitivity to antimicrobial agents. J Pharm Biomed Anal 2018;152:271-8. [PMID: 29448222 DOI: 10.1016/j.jpba.2018.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Alcedo J, Gracia M, García-cámara P, Palacín C, Gallego S, Jimeno-ayllon C, Frago S, Aured I, Luzón L. Prospective comparative study between two first-line regimens for Helicobacter pylori eradication: Non-bismuth quadruple versus bismuth quadruple therapy. Gastroenterología y Hepatología 2020;43:301-9. [DOI: 10.1016/j.gastrohep.2019.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
67 Boltin D, Schmilovitz-weiss  H, Gingold-belfer R, Leibovitzh  H, Snir Y, Perets  T, Dickman R, Levi Z, Niv Y. Temporal Trends in <b><i>Helicobacter pylori</i></b> Eradication Success in a Test-and-Treat Population. Digestion 2018;98:169-74. [DOI: 10.1159/000488448] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
68 Pohl D, Keller PM, Bordier V, Wagner K. Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing. World J Gastroenterol 2019; 25(32): 4629-4660 [PMID: 31528091 DOI: 10.3748/wjg.v25.i32.4629] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
69 Nezami BG, Jani M, Alouani D, Rhoads DD, Sadri N. Helicobacter pylori Mutations Detected by Next-Generation Sequencing in Formalin-Fixed, Paraffin-Embedded Gastric Biopsy Specimens Are Associated with Treatment Failure. J Clin Microbiol. 2019;57:pii: e01834-18. [PMID: 31068413 DOI: 10.1128/jcm.01834-18] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 5.7] [Reference Citation Analysis]
70 Tan B, Luo HQ, Xu H, Lv NH, Shi RH, Luo HS, Li JS, Ren JL, Zou YY, Li YQ, Ji F, Fang JY, Qian JM. Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. PLoS One 2017;12:e0175625. [PMID: 28407007 DOI: 10.1371/journal.pone.0175625] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
71 Tang Y, Tang G, Pan L, Zhu H, Zhou S, Wei Z. Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China. Sci Rep 2020;10:15403. [PMID: 32958842 DOI: 10.1038/s41598-020-72400-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
72 Thung I, Crowe SE, Valasek MA. Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. Authors’ reply. Aliment Pharmacol Ther 2016;43:1249-50. [DOI: 10.1111/apt.13625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Li XH, Huang YY, Lu LM, Zhao LJ, Luo XK, Li RJ, Dai YY, Qin C, Huang YQ, Chen H. Early genetic diagnosis of clarithromycin resistance in Helicobacter pyloriWorld J Gastroenterol 2021; 27(24): 3595-3608 [PMID: 34239272 DOI: 10.3748/wjg.v27.i24.3595] [Reference Citation Analysis]
74 Siddique O, Moss SF. Editorial: Helicobacter pylori resistance and sequential therapy. Aliment Pharmacol Ther 2018;48:95-6. [DOI: 10.1111/apt.14643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Huang X, Liu Y, Lin Z, Wu B, Nong G, Chen Y, Lu Y, Ji X, Zhou X, Suo B, Chen Q, Wei J. Minimum inhibitory concentrations of commonly used antibiotics against Helicobacter Pylori: A multicenter study in South China. PLoS One 2021;16:e0256225. [PMID: 34473713 DOI: 10.1371/journal.pone.0256225] [Reference Citation Analysis]
76 Nyssen OP, Perez-Aisa A, Castro-Fernandez M, Pellicano R, Huguet JM, Rodrigo L, Ortuñ J, O, Gomez-Rodriguez BJ, Pinto RM, Areia M, Perona M, Nuñez O, Romano M, Gravina AG, Pozzati L, Fernandez-Bermejo M, Venerito M, Malfertheiner P, Fernanadez-Salazar L, Gasbarrini A, Vaira D, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg investigators. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. United European Gastroenterol J 2021;9:38-46. [PMID: 33176617 DOI: 10.1177/2050640620972615] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
77 Rizvanov AA, Haertlé T, Bogomolnaya L, Talebi Bezmin Abadi A. Helicobacter pylori and Its Antibiotic Heteroresistance: A Neglected Issue in Published Guidelines. Front Microbiol 2019;10:1796. [PMID: 31456763 DOI: 10.3389/fmicb.2019.01796] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
78 Khan S, Sharaf M, Ahmed I, Khan TU, Shabana S, Arif M, Kazmi SSUH, Liu C. Potential utility of nano-based treatment approaches to address the risk of Helicobacter pylori. Expert Rev Anti Infect Ther 2021;:1-18. [PMID: 34658307 DOI: 10.1080/14787210.2022.1990041] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Wu MC, Wang YK, Liu CJ, Yu FJ, Kuo FC, Liu ML, Kuo CH, Wu DC, Huang YK, Wu IC. Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori. Gastroenterol Res Pract 2017;2017:5320180. [PMID: 28791044 DOI: 10.1155/2017/5320180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
80 Cardos IA, Zaha DC, Sindhu RK, Cavalu S. Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies. Molecules 2021;26:6078. [PMID: 34641620 DOI: 10.3390/molecules26196078] [Reference Citation Analysis]
81 Sousa C, Ferreira R, Azevedo NF, Oleastro M, Azeredo J, Figueiredo C, Melo LDR. Helicobacter pylori infection: from standard to alternative treatment strategies. Crit Rev Microbiol 2021;:1-21. [PMID: 34569892 DOI: 10.1080/1040841X.2021.1975643] [Reference Citation Analysis]
82 Zhang Q, Wu W, Zhang J, Xia X. Eradication of Helicobacter pylori: the power of nanosized formulations. Nanomedicine (Lond) 2020;15:527-42. [PMID: 32028847 DOI: 10.2217/nnm-2019-0329] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
83 Iqbal U, Khara HS, Akhtar D, Hu Y, Anwar H, Haq KF, Siddiqui HU, Bergenstock MK, Shellenberger MJ. Safety and Efficacy of Nitazoxanide-Based Regimen for the Eradication of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Gastroenterology Res 2020;13:260-8. [PMID: 33447305 DOI: 10.14740/gr1342] [Reference Citation Analysis]
84 Kim BJ, Lee H, Lee YC, Jeon SW, Kim GH, Kim HS, Sung JK, Lee DH, Kim HU, Park MI, Choi IJ, Yoon SM, Kim SW, Baik GH, Lee JY, Kim JI, Kim SG, Kim J, Lee J, Kim JG, Kim JJ;  Korean College of Helicobacter Upper Gastrointestinal Research. Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea. Gut Liver. 2019;13:531-540. [PMID: 31505907 DOI: 10.5009/gnl19136] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
85 Safarov T, Kiran B, Bagirova M, Allahverdiyev AM, Abamor ES. An overview of nanotechnology-based treatment approaches against Helicobacter Pylori. Expert Review of Anti-infective Therapy 2019;17:829-40. [DOI: 10.1080/14787210.2019.1677464] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
86 Arunachalam K, Damazo AS, Pavan E, Oliveira DM, Figueiredo FDF, Machado MTM, Balogun SO, Soares IM, Barbosa RDS, Alvim TDC, Ascêncio SD, Martins DTDO. Cochlospermum regium (Mart. ex Schrank) Pilg.: Evaluation of chemical profile, gastroprotective activity and mechanism of action of hydroethanolic extract of its xylopodium in acute and chronic experimental models. Journal of Ethnopharmacology 2019;233:101-14. [DOI: 10.1016/j.jep.2019.01.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
87 Burgos‐santamaría D, Mcnicholl AG, Gisbert JP. Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1200 patients. GastroHep 2019;1:311-24. [DOI: 10.1002/ygh2.372] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
88 Lopo I, Libânio D, Pita I, Dinis-ribeiro M, Pimentel-nunes P. Helicobacter pylori antibiotic resistance in Portugal: Systematic review and meta-analysis. Helicobacter 2018;23:e12493. [DOI: 10.1111/hel.12493] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
89 Hosseini RS, Rahimian G, Shafigh MH, Validi M, Khaledi M, Gholipour A. Correlation between clarithromycin resistance, virulence factors and clinical characteristics of the disease in Helicobacter pylori infected patients in Shahrekord, Southwest Iran. AMB Express 2021;11:147. [PMID: 34731345 DOI: 10.1186/s13568-021-01310-9] [Reference Citation Analysis]
90 Hu JL, Yang J, Zhou YB, Li P, Han R, Fang DC. Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China. Saudi J Gastroenterol. 2017;23:275-280. [PMID: 28937021 DOI: 10.4103/sjg.sjg_91_17] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
91 Saracino IM, Fiorini G, Zullo A, Pavoni M, Saccomanno L, Vaira D. Trends in Primary Antibiotic Resistance in H. pylori Strains Isolated in Italy between 2009 and 2019. Antibiotics (Basel) 2020;9:E26. [PMID: 31941121 DOI: 10.3390/antibiotics9010026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
92 Liu Q, Meng X, Li Y, Zhao CN, Tang GY, Li S, Gan RY, Li HB. Natural Products for the Prevention and Management of Helicobacter pylori Infection. Compr Rev Food Sci Food Saf 2018;17:937-52. [PMID: 33350111 DOI: 10.1111/1541-4337.12355] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
93 Urrutia-Baca VH, Escamilla-García E, de la Garza-Ramos MA, Tamez-Guerra P, Gomez-Flores R, Urbina-Ríos CS. In Vitro Antimicrobial Activity and Downregulation of Virulence Gene Expression on Helicobacter pylori by Reuterin. Probiotics Antimicrob Proteins 2018;10:168-75. [PMID: 29103130 DOI: 10.1007/s12602-017-9342-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
94 Park SM, Kim JS, Kim BW, Ji JS, Choi H. Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. J Gastroenterol Hepatol. 2017;32:589-594. [PMID: 27505301 DOI: 10.1111/jgh.13510] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
95 Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22. [PMID: 28464347 DOI: 10.1111/hel.12392] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
96 Krueger E, Brown AC. Inhibition of bacterial toxin recognition of membrane components as an anti-virulence strategy. J Biol Eng 2019;13:4. [PMID: 30820243 DOI: 10.1186/s13036-018-0138-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
97 Hsieh MS, Kuo FC, Wu MC, Wang JW, Liu CJ, Chu NS, Tsai PY, Hsu PI, Wu IC, Wu JY, Wu DC, Yu FJ, Kuo CH. Tailored susceptibility-guided therapy via gastric juice PCR for the first-line H. pylori eradication, a randomized controlled trial. J Formos Med Assoc 2021:S0929-6646(21)00483-6. [PMID: 34836662 DOI: 10.1016/j.jfma.2021.10.011] [Reference Citation Analysis]
98 Ma J, Hiratsuka T, Etoh T, Akada J, Fujishima H, Shiraishi N, Yamaoka Y, Inomata M. Anti-proliferation effect of blue light-emitting diodes against antibiotic-resistant Helicobacter pylori: Blue LED against H. pylori. Journal of Gastroenterology and Hepatology 2018;33:1492-9. [DOI: 10.1111/jgh.14066] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
99 Mehrotra T, Devi TB, Kumar S, Talukdar D, Karmakar SP, Kothidar A, Verma J, Kumari S, Alexander SM, Retnakumar RJ, Devadas K, Ray A, Mutreja A, Nair GB, Chattopadhyay S, Das B. Antimicrobial resistance and virulence in Helicobacter pylori: Genomic insights. Genomics 2021;113:3951-66. [PMID: 34619341 DOI: 10.1016/j.ygeno.2021.10.002] [Reference Citation Analysis]
100 Peng C, Sang S, Shen X, Zhang W, Yan J, Chen P, Jiang C, Yuan Y, Zhu W, Yao M. In vitro anti-Helicobacter pylori activity of Syzygium aromaticum and the preliminary mechanism of action. J Ethnopharmacol 2022;:114995. [PMID: 35032584 DOI: 10.1016/j.jep.2022.114995] [Reference Citation Analysis]
101 Tanabe H, Yoshino K, Ando K, Nomura Y, Ohta K, Satoh K, Ichiishi E, Ishizuka A, Otake T, Kohgo Y, Fujiya M, Okumura T. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Clin Microbiol Antimicrob 2018;17:29. [PMID: 29950163 DOI: 10.1186/s12941-018-0281-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
102 Smith S, Boyle B, Brennan D, Buckley M, Crotty P, Doyle M, Farrell R, Hussey M, Kevans D, Malfertheiner P. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. Eur J Gastroenterol Hepatol. 2017;29:552-559. [PMID: 28350745 DOI: 10.1097/meg.0000000000000822] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
103 Silva GM, Silva HM, Nascimento J, Gonçalves J, Pereira F, Lima R. Helicobacter pylori antimicrobial resistance in a pediatric population. Helicobacter 2018;23:e12528. [DOI: 10.1111/hel.12528] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
104 Fraser AG. Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. Aliment Pharmacol Ther 2017;46:550-1. [DOI: 10.1111/apt.14198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
105 Binmaeil H, Hanafiah A, Mohamed Rose I, Raja Ali RA. Development and Validation of Multiplex Quantitative PCR Assay for Detection of Helicobacter pylori and Mutations Conferring Resistance to Clarithromycin and Levofloxacin in Gastric Biopsy. Infect Drug Resist 2021;14:4129-45. [PMID: 34675558 DOI: 10.2147/IDR.S325056] [Reference Citation Analysis]
106 Chen D, Cunningham SA, Cole NC, Kohner PC, Mandrekar JN, Patel R. Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. Antimicrob Agents Chemother 2017;61:e02530-16. [PMID: 28167563 DOI: 10.1128/AAC.02530-16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
107 Mascellino MT, Oliva A, Miele MC, De Angelis M, Bruno G, Severi C. Secondary Antibiotic Resistance, Correlation between Genotypic and Phenotypic Methods and Treatment in Helicobacter pylori Infected Patients: A Retrospective Study. Antibiotics (Basel) 2020;9:E549. [PMID: 32872117 DOI: 10.3390/antibiotics9090549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
108 Shah CP, Purushothaman G, Thiruvenkatam V, Kirubakaran S, Juvale K, Kharkar PS. Design, synthesis and biological evaluation of Helicobacter pylori inosine 5′-monophosphate dehydrogenase (HpIMPDH) inhibitors. Further optimization of selectivity towards HpIMPDH over human IMPDH2. Bioorganic Chemistry 2019;87:753-64. [DOI: 10.1016/j.bioorg.2019.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
109 Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155: 1372-1382. e17. [PMID: 29990487 DOI: 10.1053/j.gastro.2018.07.007] [Cited by in Crossref: 274] [Cited by in F6Publishing: 238] [Article Influence: 68.5] [Reference Citation Analysis]
110 Wands DIF, El-Omar EM, Hansen R. Helicobacter pylori: getting to grips with the guidance. Frontline Gastroenterol 2021;12:650-5. [PMID: 34917323 DOI: 10.1136/flgastro-2020-101571] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Seyedmajidi MR, Hosseini SA, Vafaeimanesh J. Comparing the Effect of Two Low-dose and High-dose Four-drug Regimens of Furazolidone in Eradicating Helicobacter Pylori. Middle East J Dig Dis 2021;13:131-8. [PMID: 34712451 DOI: 10.34172/mejdd.2021.216] [Reference Citation Analysis]
112 Zhang J, Han C, Lu WQ, Wang N, Wu SR, Wang YX, Ma JP, Wang JH, Hao C, Yuan DH, Liu N, Shi YQ. A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment. J Dig Dis 2020;21:256-63. [PMID: 32348007 DOI: 10.1111/1751-2980.12870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
113 Ji CR, Liu J, Li YY, Qiao C, Qu JY, Hu JN, Lin MJ, Ji R, Li LX, Zuo XL, Li YQ. Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial. J Dig Dis 2020;21:549-57. [PMID: 32833285 DOI: 10.1111/1751-2980.12934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Mei H, Tu H. Vitamin C and Helicobacter pylori Infection: Current Knowledge and Future Prospects. Front Physiol 2018;9:1103. [PMID: 30154733 DOI: 10.3389/fphys.2018.01103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
115 Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Antonelli G, Cavallo R, Borghi C, Vaira D. Rescue Therapies for Helicobacter pylori Infection in Foreign Patients Treated in Italy. J Clin Gastroenterol 2021;55:865-8. [PMID: 33136782 DOI: 10.1097/MCG.0000000000001457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 González MF, Díaz P, Sandoval-Bórquez A, Herrera D, Quest AFG. Helicobacter pylori Outer Membrane Vesicles and Extracellular Vesicles from Helicobacter pylori-Infected Cells in Gastric Disease Development. Int J Mol Sci 2021;22:4823. [PMID: 34062919 DOI: 10.3390/ijms22094823] [Reference Citation Analysis]
117 Li M, Sun Y, Yang J, Martel C, Charvat H, Clifford GM, Vaccarella S, Wang L. Time trends and other sources of variation in Helicobacter pylori infection in mainland China: A systematic review and meta‐analysis. Helicobacter 2020;25. [DOI: 10.1111/hel.12729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
118 Peng X, Gao S, Zhang J. Gallium (III) Complexes in Cancer Chemotherapy. Euro J of Inorganic Chem. [DOI: 10.1002/ejic.202100953] [Reference Citation Analysis]
119 An Y, Wang Y, Wu S, Wang YH, Qian X, Li Z, Fu YJ, Xie Y. Fourth-generation quinolones in the treatment of Helicobacter pylori infection: A meta-analysis. World J Gastroenterol 2018; 24(29): 3302-3312 [PMID: 30090010 DOI: 10.3748/wjg.v24.i29.3302] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
120 Lee JW, Kim N, Nam RH, Jang JY, Choi Y, Lee DH. Favorable outcomes of rescue second- or third-line culture-based Helicobacter pylori eradication treatment in areas of high antimicrobial resistance. Helicobacter 2021;:e12844. [PMID: 34382277 DOI: 10.1111/hel.12844] [Reference Citation Analysis]
121 Beheshtirouy S, Eyvazi S, Tarhriz V. Evaluation of Mutations in 23S rRNA, rdxA and frxA Genes of Helicobacter pylori in Paraffin-Embedded Gastric Biopsy Specimens from Iranian Gastric Cancer and Gastritis Patients. J Gastrointest Cancer 2021;52:207-11. [PMID: 32130658 DOI: 10.1007/s12029-020-00386-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Tharmalingam N, Port J, Castillo D, Mylonakis E. Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori. Sci Rep 2018;8:3701. [PMID: 29487357 DOI: 10.1038/s41598-018-22037-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 11.8] [Reference Citation Analysis]
123 Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis. Helicobacter. 2019;24:e12565. [PMID: 30698318 DOI: 10.1111/hel.12565] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
124 Sharndama HC, Mba IE. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. Braz J Microbiol 2022. [PMID: 34988937 DOI: 10.1007/s42770-021-00675-0] [Reference Citation Analysis]
125 Wang D, Gong YH, Yuan Y. Bacterial factors associated with Helicobacter pylori antibiotic resistance. Shijie Huaren Xiaohua Zazhi 2016; 24(29): 4102-4109 [DOI: 10.11569/wcjd.v24.i29.4102] [Reference Citation Analysis]
126 Wang G, Pang J, Hu X, Nie T, Lu X, Li X, Wang X, Lu Y, Yang X, Jiang J, Li C, Xiong YQ, You X. Daphnetin: A Novel Anti-Helicobacter pylori Agent. Int J Mol Sci 2019;20:E850. [PMID: 30781382 DOI: 10.3390/ijms20040850] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
127 Zhong Y, Tang L, Deng Q, Jing L, Zhang J, Zhang Y, Yu F, Ou Y, Guo S, Huang B, Cao H, Huang P, Xu Y. Unraveling the Novel Effect of Patchouli Alcohol Against the Antibiotic Resistance of Helicobacter pylori. Front Microbiol 2021;12:674560. [PMID: 34149664 DOI: 10.3389/fmicb.2021.674560] [Reference Citation Analysis]
128 Li Y, Lv T, He C, Wang H, Cram DS, Zhou L, Zhang J, Jiang W. Evaluation of multiplex ARMS-PCR for detection of Helicobacter pylori mutations conferring resistance to clarithromycin and levofloxacin. Gut Pathog 2020;12:35. [PMID: 32670416 DOI: 10.1186/s13099-020-00373-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
129 Sahu NU, Purushothaman G, Thiruvenkatam V, Kharkar PS. Design, synthesis, and biological evaluation of Helicobacter pylori inosine 5'-monophosphate dehydrogenase (HpIMPDH) inhibitors. Drug Dev Res 2019;80:125-32. [PMID: 30381846 DOI: 10.1002/ddr.21467] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
130 Wang T, Yang X, Li Y, Li L, Liu J, Ji C, Sun Y, Li Y, Zuo X. Twice daily short-message-based re-education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study. Helicobacter. 2019;24:e12569. [PMID: 30848868 DOI: 10.1111/hel.12569] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
131 Zamani M, Zamani V, Derakhshan MH, Shokri-Shirvani J. The efficacy of first-line regimens for Helicobacter pylori eradication in different continents: A systematic review and network meta-analysis protocol. Medicine (Baltimore). 2018;97:e13682. [PMID: 30558078 DOI: 10.1097/md.0000000000013682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
132 Mestrovic A, Perkovic N, Bozic J, Pavicic Ivelja M, Vukovic J, Kardum G, Puljiz Z, Tonkic A. Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection. PLoS One 2020;15:e0244500. [PMID: 33378403 DOI: 10.1371/journal.pone.0244500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Galal AMF, Mohamed HS, Abdel-Aziz MM, Hanna AG. Development, synthesis, and biological evaluation of sulfonyl-α-l-amino acids as potential anti-Helicobacter pylori and IMPDH inhibitors. Arch Pharm (Weinheim) 2021;354:e2000385. [PMID: 33576040 DOI: 10.1002/ardp.202000385] [Reference Citation Analysis]
134 Kusunoki M, Yuki M, Ishitobi H, Kobayashi Y, Nagaoka M, Takahashi Y, Fukuba N, Komazawa Y, Shizuku T, Kinoshita Y. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication. Intern Med 2019;58:1549-55. [PMID: 30713328 DOI: 10.2169/internalmedicine.2233-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
135 Yang X, Wang JX, Han SX, Gao CP. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e14396. [PMID: 30762742 DOI: 10.1097/md.0000000000014396] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 6.7] [Reference Citation Analysis]
136 Rhodes LA PharmD. Practical considerations for managing Helicobacter pylori in college health. J Am Coll Health 2017;65:361-2. [PMID: 28622096 DOI: 10.1080/07448481.2017.1341901] [Reference Citation Analysis]
137 Kocsmár É, Kocsmár I, Buzás GM, Szirtes I, Wacha J, Takáts A, Hritz I, Schaff Z, Rugge M, Fassan M, Kiss A, Lotz G. Helicobacter pylori heteroresistance to clarithromycin in adults-New data by in situ detection and improved concept. Helicobacter 2020;25:e12670. [PMID: 31701608 DOI: 10.1111/hel.12670] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
138 Debraekeleer A, Remaut H. Future perspective for potential Helicobacter pylori eradication therapies. Future Microbiology 2018;13:671-87. [DOI: 10.2217/fmb-2017-0115] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
139 Zagari RM, Frazzoni L, Marasco G, Fuccio L, Bazzoli F. Treatment of Helicobacter pylori infection: a clinical practice update. Minerva Med 2021;112:281-7. [PMID: 32700868 DOI: 10.23736/S0026-4806.20.06810-X] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 Chu A, Wang D, Guo Q, Lv Z, Yuan Y, Gong Y. Molecular detection of H. pylori antibiotic‐resistant genes and molecular docking analysis. FASEB j 2020;34:610-8. [DOI: 10.1096/fj.201900774r] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
141 Milivojevic V, Milosavljevic T. Burden of Gastroduodenal Diseases from the Global Perspective. Curr Treat Options Gastroenterol 2020. [PMID: 31993967 DOI: 10.1007/s11938-020-00277-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
142 Fiorini G, Zullo A, Saracino IM, Pavoni M, Vaira D. Antibiotic resistance pattern of Helicobacter pylori strains isolated in Italy during 2010–2016. Scandinavian Journal of Gastroenterology 2018;53:661-4. [DOI: 10.1080/00365521.2018.1464596] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
143 Matsumoto H, Shiotani A, Graham DY. Current and Future Treatment of Helicobacter pylori Infections. Adv Exp Med Biol 2019;1149:211-25. [PMID: 31016626 DOI: 10.1007/5584_2019_367] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
144 Deguchi H, Yamazaki H, Yamamoto Y, Fukuhara S. Association between parental history of Helicobacter pylori treatment failure and treatment failure in the offspring. Journal of Gastroenterology and Hepatology 2019;34:2112-7. [DOI: 10.1111/jgh.14774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
145 Obaidat MM, Roess AA. First nationwide seroepidemiology and risk factors report of Helicobater pylori in Jordan. Helicobacter 2019;24:e12572. [PMID: 30868689 DOI: 10.1111/hel.12572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
146 Boltin D, Levi Z, Gingold-Belfer R, Gabay H, Shochat T, Niv Y, Dickman R, Dotan I, Birkenfeld S. Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes. Am J Gastroenterol 2019;114:900-6. [PMID: 31095531 DOI: 10.14309/ajg.0000000000000223] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
147 Abdelghany A, El-Desouky MA, Shemis M. Synthesis and characterization of amoxicillin-loaded polymeric nanocapsules as a drug delivery system targeting Helicobacter pylori. Arab J Gastroenterol 2021:S1687-1979(21)00044-7. [PMID: 34509390 DOI: 10.1016/j.ajg.2021.06.002] [Reference Citation Analysis]
148 Muñoz-Gómez P, Jordán-Castro JA, Abanades-Tercero M, Blanco-González JJ, Andrés Esteban EM, Valle-Muñoz J. Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. Helicobacter 2018;23. [PMID: 29178562 DOI: 10.1111/hel.12452] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
149 Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? Therap Adv Gastroenterol. 2020;13:1756284820968736. [PMID: 33240392 DOI: 10.1177/1756284820968736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
150 Yanyan S, Yanlei G, Ting Z, Shigang D. Hydrotalcite Can Prevent the Damaging Effects of Helicobacter Pylori on Gastric Epithelial Cells. Microsc Microanal 2018;24:277-83. [PMID: 29952282 DOI: 10.1017/S1431927618000314] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Kalfus IN, Graham DY, Riff DS, Panas RM. Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial. Antibiotics (Basel) 2020;9:E685. [PMID: 33050205 DOI: 10.3390/antibiotics9100685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
152 Murata M, Sugimoto M, Mizuno H, Kanno T, Satoh K. Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis. J Clin Med 2020;9:E543. [PMID: 32079208 DOI: 10.3390/jcm9020543] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
153 De R, Sarkar A, Ghosh P, Ganguly M, Karmakar BC, Saha DR, Halder A, Chowdhury A, Mukhopadhyay AK. Antimicrobial activity of ellagic acid against Helicobacter pylori isolates from India and during infections in mice. J Antimicrob Chemother 2018;73:1595-603. [PMID: 29566160 DOI: 10.1093/jac/dky079] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
154 Camorlinga-Ponce M, Gómez-Delgado A, Aguilar-Zamora E, Torres RC, Giono-Cerezo S, Escobar-Ogaz A, Torres J. Phenotypic and Genotypic Antibiotic Resistance Patterns in Helicobacter pylori Strains From Ethnically Diverse Population in México. Front Cell Infect Microbiol 2020;10:539115. [PMID: 33643927 DOI: 10.3389/fcimb.2020.539115] [Reference Citation Analysis]
155 Suzuki H, Matsuzaki J. Gastric cancer: evidence boosts Helicobacter pylori eradication. Nat Rev Gastroenterol Hepatol 2018;15:458-60. [DOI: 10.1038/s41575-018-0023-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
156 Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther. 2018;16:679-687. [PMID: 30102559 DOI: 10.1080/14787210.2018.1511427] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
157 Miehlke S, Frederking D, Günther T, Glocker E, Eisele B, Andresen V, Schröder S, Morgner A. Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population. Helicobacter 2017;22:e12429. [DOI: 10.1111/hel.12429] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
158 Adejumo AC, Labonte P, Bukong TN. Relationship Between Recreational Cannabis Use and Helicobacter pylori Infection. Cannabis Cannabinoid Res 2021. [PMID: 34748370 DOI: 10.1089/can.2021.0139] [Reference Citation Analysis]
159 Sverdén E, Markar SR, Agreus L, Lagergren J. Acute upper gastrointestinal bleeding.BMJ. 2018;363:k4023. [PMID: 30361444 DOI: 10.1136/bmj.k4023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
160 Narczyk M, Bertoša B, Papa L, Vuković V, Leščić Ašler I, Wielgus-Kutrowska B, Bzowska A, Luić M, Štefanić Z. Helicobacter pylori purine nucleoside phosphorylase shows new distribution patterns of open and closed active site conformations and unusual biochemical features. FEBS J 2018;285:1305-25. [PMID: 29430816 DOI: 10.1111/febs.14403] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
161 Lian DW, Xu YF, Deng QH, Lin XM, Huang B, Xian SX, Huang P. Effect of patchouli alcohol on macrophage mediated Helicobacter pylori digestion based on intracellular urease inhibition. Phytomedicine 2019;65:153097. [PMID: 31568921 DOI: 10.1016/j.phymed.2019.153097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
162 Jansson L, Agardh D. Prevalence of clarithromycin-resistant Helicobacter pylori in children living in South of Sweden: a 12-year follow-up. Scandinavian Journal of Gastroenterology 2019;54:838-42. [DOI: 10.1080/00365521.2019.1637452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
163 Bruno G, Rocco G, Zaccari P, Porowska B, Mascellino MT, Severi C. Helicobacter pylori Infection and Gastric Dysbiosis: Can Probiotics Administration Be Useful to Treat This Condition? Can J Infect Dis Med Microbiol. 2018;2018:6237239. [PMID: 30275917 DOI: 10.1155/2018/6237239] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
164 Choi YI, Lee SM, Chung JW, Kim KO, Kwon KA, Kim YJ, Kim JH, Lee SM, Jeong JY, Park DK. Therapeutic Potential of Sitafloxacin as a New Drug Candidate for Helicobacter Eradication in Korea: An In Vitro Culture-Based Study. Antibiotics (Basel) 2021;10:1242. [PMID: 34680822 DOI: 10.3390/antibiotics10101242] [Reference Citation Analysis]
165 Zhu YJ, Zhang Y, Wang TY, Zhao JT, Zhao Z, Zhu JR, Lan CH. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Therap Adv Gastroenterol 2020;13:1756284820937115. [PMID: 33110448 DOI: 10.1177/1756284820937115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
166 Zhou JJ, Shi X, Zheng SP, Tang D, Cai T, Yao Y, Wang F. Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China. Helicobacter 2020;25:e12755. [PMID: 32914914 DOI: 10.1111/hel.12755] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
167 Hirata Y, Serizawa T, Shichijo S, Suzuki N, Sakitani K, Hayakawa Y, Yamada A, Koike K. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen. Int J Infect Dis. 2016;51:66-69. [PMID: 27590563 DOI: 10.1016/j.ijid.2016.08.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
168 Soluri MF, Puccio S, Caredda G, Edomi P, D'Elios MM, Cianchi F, Troilo A, Santoro C, Sblattero D, Peano C. Defining the Helicobacter pylori Disease-Specific Antigenic Repertoire. Front Microbiol 2020;11:1551. [PMID: 32849324 DOI: 10.3389/fmicb.2020.01551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
169 Fiori-Duarte AT, de Oliveira Guarnieri JP, de Oliveira Borlot JRP, Lancellotti M, Rodrigues RP, Kitagawa RR, Kawano DF. In silico design and in vitro assessment of anti-Helicobacter pylori compounds as potential small-molecule arginase inhibitors. Mol Divers 2022. [PMID: 34997872 DOI: 10.1007/s11030-021-10371-8] [Reference Citation Analysis]
170 Rhie SY, Park JY, Shin TS, Kim JW, Kim BJ, Kim JG. Discovery of a Novel Mutation in DNA Gyrase and Changes in the Fluoroquinolone Resistance of Helicobacter pylori over a 14-Year Period: A Single Center Study in Korea. Antibiotics (Basel) 2020;9:E287. [PMID: 32471292 DOI: 10.3390/antibiotics9060287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
171 Shu X, Yin G, Liu M, Peng K, Zhao H, Jiang M. Antibiotics resistance of Helicobacter pylori in children with upper gastrointestinal symptoms in Hangzhou, China. Helicobacter. 2018;23:e12481. [PMID: 29528162 DOI: 10.1111/hel.12481] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
172 Schubert JP, Gehlert J, Rayner CK, Roberts-Thomson IC, Costello S, Mangoni AA, Bryant RV. Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1450-6. [PMID: 33217029 DOI: 10.1111/jgh.15352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Zamani M, Vahedi A, Maghdouri Z, Shokri-Shirvani J. Role of food in environmental transmission of Helicobacter pylori. Caspian J Intern Med. 2017;8:146-152. [PMID: 28932364 DOI: 10.22088/cjim.8.3.146] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
174 Gong Y, Yuan Y. Resistance mechanisms of Helicobacter pylori and its dual target precise therapy. Crit Rev Microbiol. 2018;44:371-392. [PMID: 29293032 DOI: 10.1080/1040841x.2017.1418285] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
175 Zhang Y, Meng F, Jin J, Wang J, Gu BB, Peng JB, Ye LP. Ninety-four thousand-case retrospective study on antibacterial drug resistance of Helicobacter pyloriWorld J Clin Cases 2021; 9(35): 10838-10849 [DOI: 10.12998/wjcc.v9.i35.10838] [Reference Citation Analysis]
176 Guo H, Lam AY, Shaheen AA, Forbes N, Kaplan GG, Andrews CN, Laffin M, Singh S, Jairath V, Teriaky A, Lee JK, Ma C. Urban-Rural Disparities and Temporal Trends in Peptic Ulcer Disease Epidemiology, Treatment, and Outcomes in the United States. Am J Gastroenterol 2021;116:296-305. [DOI: 10.14309/ajg.0000000000000997] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Kim JJE, Kocsmár I, Buzás GM, Szirtes I, Rusz O, Diczházi C, Szijártó A, Hritz I, Schaff Z, Kiss A, Kocsmár É, Lotz G. Efficacy of Clarithromycin Depends on the Bacterial Density in Clarithromycin-Heteroresistant Helicobacter pylori Infections: An In Situ Detected Susceptibility and Quantitative Morphometry-Based Retrospective Study. Pathol Oncol Res 2021;27:1609863. [PMID: 34267605 DOI: 10.3389/pore.2021.1609863] [Reference Citation Analysis]
178 Bkhaitan MM, Alarjah M, Mirza AZ, Abdalla AN, El-Said HM, Faidah HS. Preparation and biological evaluation of metronidazole derivatives with monoterpenes and eugenol. Chem Biol Drug Des 2018;92:1954-62. [PMID: 30022596 DOI: 10.1111/cbdd.13366] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
179 Talebi Bezmin Abadi A, Yamaoka Y. Helicobacter pylori therapy and clinical perspective. Journal of Global Antimicrobial Resistance 2018;14:111-7. [DOI: 10.1016/j.jgar.2018.03.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
180 Luo L, Huang Y, Liang X, Ji Y, Yu L, Lu H. Susceptibility‐guided therapy for Helicobacter pylori ‐infected penicillin‐allergic patients: A prospective clinical trial of first‐line and rescue therapies. Helicobacter 2020;25. [DOI: 10.1111/hel.12699] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
181 Cai Y, Wang C, Chen Z, Xu Z, Li H, Li W, Sun Y. Transporters HP0939, HP0497, and HP0471 participate in intrinsic multidrug resistance and biofilm formation in Helicobacter pylori by enhancing drug efflux. Helicobacter 2020;25:e12715. [PMID: 32548895 DOI: 10.1111/hel.12715] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
182 Jaka H, Rüttgerodt N, Bohne W, Mueller A, Gross U, Kasang C, Mshana SE. Helicobacter pylori Mutations Conferring Resistance to Fluoroquinolones and Clarithromycin among Dyspeptic Patients Attending a Tertiary Hospital, Tanzania. Can J Gastroenterol Hepatol 2019;2019:8481375. [PMID: 31355162 DOI: 10.1155/2019/8481375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
183 Losurdo G, Gravina AG, Maroni L, Gabrieletto EM, Ianiro G, Ferrarese A; Young Investigator group of SIGE, the Italian Society of Gastroenterology. Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Dig Liver Dis 2021:S1590-8658(21)00455-2. [PMID: 34509394 DOI: 10.1016/j.dld.2021.08.008] [Reference Citation Analysis]
184 Ghidey M, Islam SMA, Pruett G, Kearney CM. Making plants into cost-effective bioreactors for highly active antimicrobial peptides. N Biotechnol 2020;56:63-70. [PMID: 31812667 DOI: 10.1016/j.nbt.2019.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
185 Miftahussurur M, Waskito LA, Syam AF, Nusi IA, Siregar G, Richardo M, Bakry AF, Rezkitha YAA, Wibawa IDN, Yamaoka Y. Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance. Infect Drug Resist. 2019;12:345-358. [PMID: 30774400 DOI: 10.2147/idr.s187063] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
186 Zhang Y, Wen Y, Xiao Q, Zheng W, Long G, Chen B, Shu X, Jiang M. Mutations in the Antibiotic Target Genes Related to Clarithromycin, Metronidazole and Levofloxacin Resistance in Helicobacter pylori Strains from Children in China. Infect Drug Resist 2020;13:311-22. [PMID: 32099422 DOI: 10.2147/IDR.S235615] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
187 Gollapalli P, G TS, H M, Shetty P, N SK. Network topology analysis of essential genes interactome of Helicobacter pylori to explore novel therapeutic targets. Microb Pathog 2021;158:105059. [PMID: 34157412 DOI: 10.1016/j.micpath.2021.105059] [Reference Citation Analysis]
188 Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P, Maldonado-Garza HJ, Garza-González E. Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol 2018;12:819-27. [PMID: 29976092 DOI: 10.1080/17474124.2018.1496017] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
189 Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter 2017;22:e12374. [DOI: 10.1111/hel.12374] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
190 Kong S, Huang K, Wang J, Wang X, Yang N, Dong Y, Zhuang Y, Dang Y, Zhang G, Ye F. Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study. Gut Pathog 2020;12:39. [PMID: 32874206 DOI: 10.1186/s13099-020-00378-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
191 Thieu H, Bach Dat B, Nam NH, Reda A, Duc NT, Alshareef A, Nguyen JG, Ngoc NM, Tien Huy N. Antibiotic resistance of Helicobacter pylori infection in a children's hospital in Vietnam: prevalence and associated factors. Minerva Med 2020;111:498-501. [PMID: 32406218 DOI: 10.23736/S0026-4806.20.06498-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Okubo H, Akiyama J, Kobayakawa M, Kawazoe M, Mishima S, Takasaki Y, Nagata N, Shimada T, Yokoi C, Komori S, Kimura K, Hisada Y, Iwata E, Watanabe K, Yanagisawa N, Shiroma S, Shimomura A, Okahara K, Cho H, Uemura N. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility. J Gastroenterol 2020;55:1054-61. [PMID: 32930864 DOI: 10.1007/s00535-020-01723-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
193 Tshibangu-Kabamba E, Ngoma-Kisoko PJ, Tuan VP, Matsumoto T, Akada J, Kido Y, Tshimpi-Wola A, Tshiamala-Kashala P, Ahuka-Mundeke S, Ngoy DM, Disashi-Tumba G, Yamaoka Y. Next-Generation Sequencing of the Whole Bacterial Genome for Tracking Molecular Insight into the Broad-Spectrum Antimicrobial Resistance of Helicobacter pylori Clinical Isolates from the Democratic Republic of Congo. Microorganisms 2020;8:E887. [PMID: 32545318 DOI: 10.3390/microorganisms8060887] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
194 Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, Megraud F, O'Morain C, Graham DY. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology 2021;161:495-507.e4. [PMID: 33839101 DOI: 10.1053/j.gastro.2021.04.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
195 Domanovich-Asor T, Motro Y, Khalfin B, Craddock HA, Peretz A, Moran-Gilad J. Genomic Analysis of Antimicrobial Resistance Genotype-to-Phenotype Agreement in Helicobacter pylori. Microorganisms 2020;9:E2. [PMID: 33374988 DOI: 10.3390/microorganisms9010002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
196 Coelho LGV, Marinho JR, Genta R, Ribeiro LT, Passos MDCF, Zaterka S, Assumpção PP, Barbosa AJA, Barbuti R, Braga LL, Breyer H, Carvalhaes A, Chinzon D, Cury M, Domingues G, Jorge JL, Maguilnik I, Marinho FP, Moraes-filho JPD, Parente JML, Paula-e-silva CMD, Pedrazzoli-júnior J, Ramos AFP, Seidler H, Spinelli JN, Zir JV. IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. Arq Gastroenterol 2018;55:97-121. [DOI: 10.1590/s0004-2803.201800000-20] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
197 周林, 赵阳鹏, 张伟. 幽门螺杆菌根除治疗在胃癌预防中的现状及前景. 世界华人消化杂志 2017; 25(15): 1327-1337 [DOI: 10.11569/wcjd.v25.i15.1327] [Reference Citation Analysis]
198 Yeo YH, Hsu CC, Lee CC, Ho HJ, Lin JT, Wu MS, Liou JM, Wu CY; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication. J Gastroenterol Hepatol 2019;34:59-67. [PMID: 30169908 DOI: 10.1111/jgh.14462] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
199 Zhang YW, Hu WL, Cai Y, Zheng WF, Du Q, Kim JJ, Kao JY, Dai N, Si JM. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J Gastroenterol 2018; 24(40): 4596-4605 [PMID: 30386109 DOI: 10.3748/wjg.v24.i40.4596] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
200 Hunt RH, Scarpignato C. Potent Acid Suppression with PPIs and P-CABs: What’s New? Curr Treat Options Gastro 2018;16:570-90. [DOI: 10.1007/s11938-018-0206-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
201 Ansari S, Yamaoka Y. Current understanding and management of Helicobacter pylori infection: an updated appraisal. F1000Res. 2018;7. [PMID: 29946428 DOI: 10.12688/f1000research.14149.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
202 Leng L, Wei L, Xiong Q, Xu S, Li W, Lv S, Lu Q, Wan L, Wen Z, Zhou W. Use of microalgae based technology for the removal of antibiotics from wastewater: A review. Chemosphere 2020;238:124680. [DOI: 10.1016/j.chemosphere.2019.124680] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 32.0] [Reference Citation Analysis]
203 Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. Nat Rev Gastroenterol Hepatol 2021;18:613-29. [PMID: 34002081 DOI: 10.1038/s41575-021-00449-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
204 Khani S, Talebi Bezmin Abadi A, Mohabati Mobarez A. Clarithromycin-Susceptible But Virulent Helicobacter pylori Strains Infecting Iranian Patients' Stomachs. Infect Drug Resist 2019;12:3415-20. [PMID: 31802920 DOI: 10.2147/IDR.S223602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
205 Kumar S, Sangitha R, Nachamkin I, Metz DC. Resistance patterns of refractory H. pylori infection in a referral center in the Delaware Valley. GastroHep 2020;2:6-12. [PMID: 32377173 DOI: 10.1002/ygh2.382] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
206 Qiao C, Li Y, Liu J, Ji C, Qu J, Hu J, Ji R, Wan M, Lin B, Lin M, Qi Q, Zuo X, Li Y. Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area. J Gastroenterol Hepatol 2021. [PMID: 33691344 DOI: 10.1111/jgh.15468] [Reference Citation Analysis]
207 Jalalypour F, Farajnia S, Somi MH, Hojabri Z, Yousefzadeh R, Saeedi N. Comparative Evaluation of RUT, PCR and ELISA Tests for Detection of Infection with Cytotoxigenic H. pylori. Adv Pharm Bull 2016;6:261-6. [PMID: 27478790 DOI: 10.15171/apb.2016.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
208 Macías-garcía F, Llovo-taboada J, Díaz-lópez M, Bastón-rey I, Domínguez-muñoz JE. High primary antibiotic resistance of Helicobacter Pylori strains isolated from dyspeptic patients: A prevalence cross-sectional study in Spain. Helicobacter 2017;22:e12440. [DOI: 10.1111/hel.12440] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
209 Sue S, Ogushi M, Arima I, Kuwashima H, Nakao S, Naito M, Komatsu K, Kaneko H, Tamura T, Sasaki T, Kondo M, Shibata W, Maeda S. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. Helicobacter. 2018;23:e12456. [PMID: 29271026 DOI: 10.1111/hel.12456] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
210 El-sherbiny GM, Elbestawy MKM. A review – plant essential oils active against Helicobacter pylori. Journal of Essential Oil Research. [DOI: 10.1080/10412905.2022.2025464] [Reference Citation Analysis]
211 Fitzgerald R, Smith SM. An Overview of Helicobacter pylori Infection. In: Smith SM, editor. Helicobacter Pylori. New York: Springer US; 2021. pp. 1-14. [DOI: 10.1007/978-1-0716-1302-3_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Wu T, Wang L, Gong M, Lin Y, Xu Y, Ye L, Yu X, Liu J, Liu J, He S, Zeng H, Wang G. Synergistic effects of nanoparticle heating and amoxicillin on H. pylori inhibition. Journal of Magnetism and Magnetic Materials 2019;485:95-104. [DOI: 10.1016/j.jmmm.2019.04.076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
213 Siddique O, Ovalle A, Siddique AS, Moss SF. Helicobacter pylori Infection: An Update for the Internist in the Age of Increasing Global Antibiotic Resistance. The American Journal of Medicine 2018;131:473-9. [DOI: 10.1016/j.amjmed.2017.12.024] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
214 Keikha M, Eslami M, Yousefi B, Ghasemian A, Karbalaei M. Potential antigen candidates for subunit vaccine development against Helicobacter pylori infection. J Cell Physiol 2019;234:21460-70. [DOI: 10.1002/jcp.28870] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
215 Kim SY, Park JM, Lim CH, Lee HA, Shin GY, Choe Y, Cho YK, Choi MG. Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for Helicobacter pylori. Gut Liver 2021;15:528-36. [PMID: 33376228 DOI: 10.5009/gnl20225] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Bubić A, Mrnjavac N, Stuparević I, Łyczek M, Wielgus-Kutrowska B, Bzowska A, Luić M, Leščić Ašler I. In the quest for new targets for pathogen eradication: the adenylosuccinate synthetase from the bacterium Helicobacter pylori. J Enzyme Inhib Med Chem 2018;33:1405-14. [PMID: 30191734 DOI: 10.1080/14756366.2018.1506773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
217 Xirouchakis E, Georgopoulos SD. Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review. Expert Opin Pharmacother 2021;:1-10. [PMID: 34595999 DOI: 10.1080/14656566.2021.1982894] [Reference Citation Analysis]
218 Merino JS, Araneda L, Lincoñir-campos P, Parra C, Sáez K, García A. Dinámica de la infección por Helicobacter pylori en lactantes durante los primeros 6 meses de vida. Enfermedades Infecciosas y Microbiología Clínica 2019;37:109-11. [DOI: 10.1016/j.eimc.2018.03.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
219 Moayedi S, Yadegar A, Balalaie S, Yarmohammadi M, Zali MR, Suzuki H, Fricker G, Haririan I. Sugar Codes Conjugated Alginate: An Innovative Platform to Make a Strategic Breakthrough in Simultaneous Prophylaxis of GERD and Helicobacter pylori Infection. Drug Des Devel Ther 2020;14:2405-12. [PMID: 32606607 DOI: 10.2147/DDDT.S255611] [Reference Citation Analysis]
220 Graham DY, Laine L. The Toronto Helicobacter pylori Consensus in Context. Gastroenterology 2016;151:9-12. [PMID: 27215659 DOI: 10.1053/j.gastro.2016.05.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
221 Egan K, Ross RP, Hill C. Bacteriocins: antibiotics in the age of the microbiome. Emerg Top Life Sci 2017;1:55-63. [PMID: 33525813 DOI: 10.1042/ETLS20160015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
222 Wang F, Feng J, Chen P, Liu X, Ma M, Zhou R, Chang Y, Liu J, Li J, Zhao Q. Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41:466-475. [PMID: 28552432 DOI: 10.1016/j.clinre.2017.04.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 8.4] [Reference Citation Analysis]
223 Yi DM, Yang TT, Chao SH, Li YX, Zhou YL, Zhang HH, Lan L, Zhang YW, Wang XM, Zhang YR, Li J, Ding SZ. Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study. Medicine (Baltimore) 2019;98:e14408. [PMID: 30732192 DOI: 10.1097/MD.0000000000014408] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
224 Ji CR, Liu J, Li YY, Guo CG, Qu JY, Zhang Y, Zuo X. Safety of furazolidone-containing regimen in Helicobacter pylori infection: a systematic review and meta-analysis. BMJ Open 2020;10:e037375. [PMID: 33077561 DOI: 10.1136/bmjopen-2020-037375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
225 Kuo CH, Liu CJ, Yang CC, Kuo FC, Hu HM, Shih HY, Wu MC, Chen YH, Wang HM, Ren JL. A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice. Medicine (Baltimore). 2016;95:e3458. [PMID: 27227911 DOI: 10.1097/md.0000000000003458] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
226 Farzi N, Yadegar A, Sadeghi A, Asadzadeh Aghdaei H, Marian Smith S, Raymond J, Suzuki H, Zali MR. High Prevalence of Antibiotic Resistance in Iranian Helicobacter pylori Isolates: Importance of Functional and Mutational Analysis of Resistance Genes and Virulence Genotyping. J Clin Med. 2019;8. [PMID: 31744181 DOI: 10.3390/jcm8112004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
227 Neshani A, Zare H, Akbari Eidgahi MR, Hooshyar Chichaklu A, Movaqar A, Ghazvini K. Review of antimicrobial peptides with anti-Helicobacter pylori activity. Helicobacter. 2019;24:e12555. [PMID: 30440101 DOI: 10.1111/hel.12555] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
228 Wylie MR, Windham IH, Blum FC, Wu H, Merrell DS. In vitro antibacterial activity of nimbolide against Helicobacter pylori. J Ethnopharmacol 2021;:114828. [PMID: 34763046 DOI: 10.1016/j.jep.2021.114828] [Reference Citation Analysis]
229 Cheesman MJ, Ilanko A, Blonk B, Cock IE. Developing New Antimicrobial Therapies: Are Synergistic Combinations of Plant Extracts/Compounds with Conventional Antibiotics the Solution? Pharmacogn Rev 2017;11:57-72. [PMID: 28989242 DOI: 10.4103/phrev.phrev_21_17] [Cited by in Crossref: 150] [Cited by in F6Publishing: 109] [Article Influence: 30.0] [Reference Citation Analysis]
230 Mosites E, Bruden D, Morris J, Reasonover A, Rudolph K, Hurlburt D, Hennessy T, McMahon B, Bruce M. Antimicrobial resistance among Helicobacter pylori isolates in Alaska, 2000-2016. J Glob Antimicrob Resist 2018;15:148-53. [PMID: 29969753 DOI: 10.1016/j.jgar.2018.06.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
231 Miftahussurur M, Pratama Putra B, Yamaoka Y. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals (Basel) 2020;13:E276. [PMID: 32998241 DOI: 10.3390/ph13100276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
232 Teng G, Liu Y, Wu T, Wang W, Wang H, Hu F. Efficacy of Sucralfate-Combined Quadruple Therapy on Gastric Mucosal Injury Induced by Helicobacter pylori and Its Effect on Gastrointestinal Flora. Biomed Res Int 2020;2020:4936318. [PMID: 32934960 DOI: 10.1155/2020/4936318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
233 Lansdorp-Vogelaar I, Meester RGS, Laszkowska M, Escudero FA, Ward ZJ, Yeh JM. Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. Best Pract Res Clin Gastroenterol 2021;50-51:101735. [PMID: 33975689 DOI: 10.1016/j.bpg.2021.101735] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
234 Quinn L, Sheh A, Ellis JL, Smith DE, Booth SL, Fu X, Muthupalani S, Ge Z, Puglisi DA, Wang TC, Gonda TA, Holcombe H, Fox JG. Helicobacter pylori antibiotic eradication coupled with a chemically defined diet in INS-GAS mice triggers dysbiosis and vitamin K deficiency resulting in gastric hemorrhage. Gut Microbes 2020;11:820-41. [PMID: 31955643 DOI: 10.1080/19490976.2019.1710092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
235 Shapla UM, Raihan J, Islam A, Alam F, Solayman N, Gan SH, Hossen S, Khalil I. Propolis: The future therapy against Helicobacter pylori-mediated gastrointestinal diseases. J Appl Biomed 2018;16:81-99. [DOI: 10.1016/j.jab.2017.10.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
236 De Francesco V, Bellesia A, Ridola L, Manta R, Zullo A. First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines. Ann Gastroenterol. 2017;30:373-379. [PMID: 28655973 DOI: 10.20524/aog.2017.0166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
237 Wang L, Lin Z, Chen S, Li J, Chen C, Huang Z, Ye B, Ding J, Li W, Wu L, Jiang Y, Meng L, Du Q, Si J. Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori –related chronic gastritis: a prospective randomized study in China. Clinical Microbiology and Infection 2017;23:391-5. [DOI: 10.1016/j.cmi.2016.12.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
238 Ji J, Yang H. In Vitro Effects of Lactobacillus plantarum LN66 and Antibiotics Used Alone or in Combination on Helicobacter pylori Mature Biofilm. Microorganisms 2021;9:424. [PMID: 33670726 DOI: 10.3390/microorganisms9020424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Keikha M, Karbalaei M. Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections. BMC Gastroenterol 2021;21:388. [PMID: 34670526 DOI: 10.1186/s12876-021-01977-1] [Reference Citation Analysis]
240 Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288] [Cited by in Crossref: 1166] [Cited by in F6Publishing: 992] [Article Influence: 194.3] [Reference Citation Analysis]
241 Farzi N, Behzad C, Hasani Z, Alebouyeh M, Zojaji H, Zali MR. Characterization of clarithromycin heteroresistance among Helicobacter pylori strains isolated from the antrum and corpus of the stomach. Folia Microbiol (Praha) 2019;64:143-51. [PMID: 30097895 DOI: 10.1007/s12223-018-0637-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
242 Marcus EA, Sachs G, Scott DR. Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep 2016;18:33. [PMID: 27177639 DOI: 10.1007/s11894-016-0509-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
243 Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017;8:123-30. [DOI: 10.1016/j.jgar.2016.11.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
244 Rasi-Bonab F, Jafari-Sales A, Shaverdi MA, Navidifar T, Saki M, Ghorbani A, Adekanmbi AO, Jafari B, Naebi S. Antibiotic resistance pattern and frequency of cagA and vacA genes in Helicobacter pylori strains isolated from patients in Tabriz city, Iran. BMC Res Notes 2021;14:216. [PMID: 34059110 DOI: 10.1186/s13104-021-05633-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Gong M, Han Y, Wang X, Tao H, Meng F, Hou B, Sun BB, Wang G. Effect of Temperature on Metronidazole Resistance in Helicobacter pylori. Front Microbiol 2021;12:681911. [PMID: 34093508 DOI: 10.3389/fmicb.2021.681911] [Reference Citation Analysis]
246 Shao Y, Lu R, Yang Y, Xu Q, Wang B, Ye G. Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients. J Clin Lab Anal. 2018;32:e22339. [PMID: 28984385 DOI: 10.1002/jcla.22339] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
247 Blum FC, Singh J, Merrell DS. In vitro activity of neem (Azadirachta indica) oil extract against Helicobacter pylori. J Ethnopharmacol 2019;232:236-43. [PMID: 30578933 DOI: 10.1016/j.jep.2018.12.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
248 Mascellino MT, Porowska B, De Angelis M, Oliva A. Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection. Drug Des Devel Ther 2017;11:2209-20. [PMID: 28814829 DOI: 10.2147/DDDT.S136240] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
249 Domanovich-Asor T, Craddock HA, Motro Y, Khalfin B, Peretz A, Moran-Gilad J. Unraveling antimicrobial resistance in Helicobacter pylori: Global resistome meets global phylogeny. Helicobacter 2021;26:e12782. [PMID: 33491828 DOI: 10.1111/hel.12782] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
250 Zhang Y, Chen Y, Lo C, Zhuang J, Angsantikul P, Zhang Q, Wei X, Zhou Z, Obonyo M, Fang RH, Gao W, Zhang L. Inhibition of Pathogen Adhesion by Bacterial Outer Membrane-Coated Nanoparticles. Angew Chem Int Ed Engl 2019;58:11404-8. [PMID: 31206942 DOI: 10.1002/anie.201906280] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
251 Zhang Y, Chen Y, Lo C, Zhuang J, Angsantikul P, Zhang Q, Wei X, Zhou Z, Obonyo M, Fang RH, Gao W, Zhang L. Inhibition of Pathogen Adhesion by Bacterial Outer Membrane‐Coated Nanoparticles. Angew Chem 2019;131:11526-30. [DOI: 10.1002/ange.201906280] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
252 Suzuki S, Esaki M, Kusano C, Ikehara H, Gotoda T. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World J Gastroenterol 2019; 25(16): 1907-1912 [PMID: 31086459 DOI: 10.3748/wjg.v25.i16.1907] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
253 Van den Poel B, Gils S, Micalessi I, Carton S, Christiaens P, Cuyle PJ, Moons V, Van Olmen G, Smismans A, Bourgain C, Bossuyt P, Frans J. Molecular detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE Helicobacter pylori assay. Acta Clin Belg 2021;76:177-83. [PMID: 31662122 DOI: 10.1080/17843286.2019.1685741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
254 Tsujimae M, Yamashita H, Hashimura H, Kano C, Shimoyama K, Kanamori A, Matsumoto K, Koizumi A, Momose K, Eguchi T, Fukuchi T, Fujita M, Okada A. A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori. Digestion 2016;94:240-6. [PMID: 28030862 DOI: 10.1159/000454762] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
255 Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Mochizuki S, Matsuo K, Isomura Y, Seto M, Suzuki N, Suzuki H, Yamamoto S, Sugimoto T, Omae T, Okamoto M, Watabe H, Togo G, Takano N, Fukui K, Ito Y, Koike K. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori : A multicenter retrospective study in clinical practice: H. pylori eradication by vonoprazan. Journal of Digestive Diseases 2016;17:670-5. [DOI: 10.1111/1751-2980.12398] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
256 Georgopoulos SD, Michopoulos S, Rokkas T, Apostolopoulos P, Giamarellos E, Kamberoglou D, Mentis A, Triantafyllou K. Hellenic consensus on Helicobacter pylori infection. Ann Gastroenterol 2020;33:105-24. [PMID: 32127732 DOI: 10.20524/aog.2020.0446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
257 Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112:212-239. [PMID: 28071659 DOI: 10.1038/ajg.2016.563] [Cited by in Crossref: 515] [Cited by in F6Publishing: 415] [Article Influence: 103.0] [Reference Citation Analysis]
258 Das R, Sureshkumar S, Sreenath GS, Kate V. Sequential versus concomitant therapy for eradication of Helicobacter Pylori in patients with perforated duodenal ulcer: A randomized trial. Saudi J Gastroenterol 2016;22:309-15. [PMID: 27488326 DOI: 10.4103/1319-3767.187605] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
259 Khademi F, Sahebkar AH, Vaez H, Arzanlou M, Peeridogaheh H. Characterization of clarithromycin-resistant Helicobacter pylori strains in Iran: A systematic review and meta-analysis. Journal of Global Antimicrobial Resistance 2017;10:171-8. [DOI: 10.1016/j.jgar.2017.05.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
260 Huang X, Sun X, Yu X, Qian H. Efficacy and safety of Sijunzi Decoction for peptic ulcers: A systematic review and meta-analysis. Journal of Traditional Chinese Medical Sciences 2018;5:237-54. [DOI: 10.1016/j.jtcms.2018.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
261 Hsu PI, Tsay FW, Kao JY, Peng NJ, Chen YH, Tang SY, Kuo CH, Kao SS, Wang HM, Wu IT, Shie CB, Chuah SK, Wu DC; Taiwan Acid-related Disease, Microbiota (TARD-M) Consortium. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection. Helicobacter 2021;:e12840. [PMID: 34390083 DOI: 10.1111/hel.12840] [Reference Citation Analysis]
262 Ji J, Yang H. Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy.Int J Mol Sci. 2020;21. [PMID: 32046317 DOI: 10.3390/ijms21031136] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
263 Lormohammadi L, Nikkhahi F, Bolori S, Karami AA, Hajian S, Rad N, Peymani A, Samimi R. High level of resistance to metronidazole and clarithromycin among Helicobacter pylori clinical isolates in Qazvin province, Iran. Gene Reports 2022. [DOI: 10.1016/j.genrep.2022.101494] [Reference Citation Analysis]
264 da Silva FAF, de Brito BB, Santos MLC, Marques HS, Sampaio MM, da Silva Júnior RT, Apolonio JS, de Carvalho LS, Silva CS, de Sá Santos LK, Oliveira MV, Rocha GA, de Magalhães Queiroz DM, de Melo FF. Treatment of Helicobacter pylori infection in children: A systematic review. World J Meta-Anal 2020; 8(4): 292-308 [DOI: 10.13105/wjma.v8.i4.292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
265 Deguchi H, Yamazaki H, Kamitani T, Yamamoto Y, Fukuhara S. Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis. Adv Ther 2021;38:3937-47. [PMID: 34091865 DOI: 10.1007/s12325-021-01784-w] [Reference Citation Analysis]
266 Kipritci Z, Gurol Y, Celik G. Antibiotic Resistance Results of Helicobacter pylori in a University Hospital: Comparison of the Hybridization Test and Real-Time Polymerase Chain Reaction. Int J Microbiol 2020;2020:8853298. [PMID: 33488727 DOI: 10.1155/2020/8853298] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Kumar S, Metz DC, Kaplan DE, Goldberg DS. Low Rates of Retesting for Eradication of Helicobacter pylori Infection After Treatment in the Veterans Health Administration. Clin Gastroenterol Hepatol 2021;19:305-313.e1. [PMID: 32272245 DOI: 10.1016/j.cgh.2020.03.059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
268 Diab M, El-shenawy A, El-ghannam M, Salem D, Abdelnasser M, Shaheen M, Abdel-hady M, El-sherbini E, Saber M. Detection of antimicrobial resistance genes of Helicobacter pylori strains to clarithromycin, metronidazole, amoxicillin and tetracycline among Egyptian patients. Egyptian Journal of Medical Human Genetics 2018;19:417-23. [DOI: 10.1016/j.ejmhg.2018.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
269 Hanafiah A, Binmaeil H, Raja Ali RA, Mohamed Rose I, Lopes BS. Molecular characterization and prevalence of antibiotic resistance in Helicobacter pylori isolates in Kuala Lumpur, Malaysia. Infect Drug Resist. 2019;12:3051-3061. [PMID: 31632095 DOI: 10.2147/idr.s219069] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
270 Scott DR, Sachs G, Marcus EA. The role of acid inhibition in Helicobacter pylori eradication. F1000Res 2016;5:F1000 Faculty Rev-1747. [PMID: 30023042 DOI: 10.12688/f1000research.8598.1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
271 Krzyżek P, Pawełka D, Iwańczak B, Kempiński R, Leśniakowski K, Mégraud F, Łaczmański Ł, Biernat M, Gościniak G. High Primary Antibiotic Resistance of Helicobacter pylori Strains Isolated from Pediatric and Adult Patients in Poland during 2016-2018. Antibiotics (Basel) 2020;9:E228. [PMID: 32370201 DOI: 10.3390/antibiotics9050228] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
272 Kasza K, Gurnani P, Hardie KR, Cámara M, Alexander C. Challenges and solutions in polymer drug delivery for bacterial biofilm treatment: A tissue-by-tissue account. Adv Drug Deliv Rev 2021;178:113973. [PMID: 34530014 DOI: 10.1016/j.addr.2021.113973] [Reference Citation Analysis]
273 Nayar DS. Current eradication rate of Helicobacter pylori with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area. Infect Drug Resist 2018;11:205-11. [PMID: 29430191 DOI: 10.2147/IDR.S153617] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
274 Murray BO, Dawson RA, Alsharaf LM, Anne Winter J. Protective effects of Helicobacter pylori membrane vesicles against stress and antimicrobial agents. Microbiology (Reading) 2020;166:751-8. [PMID: 32463354 DOI: 10.1099/mic.0.000934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
275 Khademi F, Sahebkar A. An Updated Systematic Review and Meta-Analysis on the Helicobacter pylori Antibiotic Resistance in Iran (2010-2020). Microb Drug Resist 2020;26:1186-94. [PMID: 32354289 DOI: 10.1089/mdr.2020.0088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
276 Oporto M, Pavez M, Troncoso C, Cerda A, Hofmann E, Sierralta A, Rios E, Coppelli L, Barrientos L. Prevalence of Infection and Antibiotic Susceptibility of Helicobacter pylori: An Evaluation in Public and Private Health Systems of Southern Chile. Pathogens 2019;8:E226. [PMID: 31717523 DOI: 10.3390/pathogens8040226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
277 Lee KY, Lee BJ. Solution NMR studies on Helicobacter pylori proteins for antibiotic target discovery. Expert Opin Drug Discov 2016;11:681-93. [PMID: 27216839 DOI: 10.1080/17460441.2016.1189411] [Reference Citation Analysis]
278 Hu W, Zhang L, Li MX, Shen J, Liu XD, Xiao ZG, Wu DL, Ho IHT, Wu JCY, Cheung CKY, Zhang YC, Lau AHY, Ashktorab H, Smoot DT, Fang EF, Chan MTV, Gin T, Gong W, Wu WKK, Cho CH. Vitamin D3 activates the autolysosomal degradation function against Helicobacter pylori through the PDIA3 receptor in gastric epithelial cells. Autophagy 2019;15:707-25. [PMID: 30612517 DOI: 10.1080/15548627.2018.1557835] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
279 Dutta AK, Phull PS. Treatment of Helicobacter pylori infection in the presence of penicillin allergy. World J Gastroenterol 2021; 27(44): 7661-7668 [PMID: 34908805 DOI: 10.3748/wjg.v27.i44.7661] [Reference Citation Analysis]
280 Jia J, Zhang C, Liu Y, Huang Y, Bai Y, Hang X, Zeng L, Zhu D, Bi H. Armeniaspirol A: a novel anti-Helicobacter pylori agent. Microb Biotechnol 2021. [PMID: 33780131 DOI: 10.1111/1751-7915.13807] [Reference Citation Analysis]
281 Zagari RM, Romano M, Frazzoni L, Marasco G, Dajti E, Arcidiacono PG, Armuzzi A, Biagi F, Cannizzaro R, Cavestro GM, Ciacci C, Monica F, Peralta S, Radaelli F, Bazzoli F. Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD. Helicobacter 2021;:e12862. [PMID: 34766392 DOI: 10.1111/hel.12862] [Reference Citation Analysis]
282 Hsieh MT, Chang WL, Wu CT, Yang HB, Kuo HY, Lin MY, Cheng HC, Tsai YC, Sheu BS. Optimizing the MIC breakpoints of amoxicillin and tetracycline for antibiotic selection in the rescue therapy of H. pylori with bismuth quadruple regimen. Eur J Clin Pharmacol 2020;76:1581-9. [PMID: 32591943 DOI: 10.1007/s00228-020-02938-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
283 Liu A, Wang Y, Song Y, Du Y. Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection. Saudi J Gastroenterol 2020;26:78-83. [PMID: 32295932 DOI: 10.4103/sjg.SJG_589_19] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
284 Silvan JM, Gutiérrez-Docio A, Moreno-Fernandez S, Alarcón-Cavero T, Prodanov M, Martinez-Rodriguez AJ. Procyanidin-Rich Extract from Grape Seeds as a Putative Tool against Helicobacter pylori. Foods 2020;9:E1370. [PMID: 32993186 DOI: 10.3390/foods9101370] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
285 Shokri-shirvani J, Zamani V, Zamani M. Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. Aliment Pharmacol Ther 2016;43:1249-1249. [DOI: 10.1111/apt.13612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
286 Spiteri JA, Zahra G, Schembri J, Pisani A, Borg E, Spiteri N, Bianco EZ, Caruana P, Gauci J, Muscat M, Barbara C, Ellul P. Identification of antibiotic resistance patterns in Helicobacter pylori strains isolated from gastric biopsies using real-time PCR and genotypic analysis. Ann Gastroenterol 2021;34:501-9. [PMID: 34276188 DOI: 10.20524/aog.2021.0624] [Reference Citation Analysis]
287 Baj J, Forma A, Flieger W, Morawska I, Michalski A, Buszewicz G, Sitarz E, Portincasa P, Garruti G, Flieger M, Teresiński G. Helicobacter pylori Infection and Extragastric Diseases-A Focus on the Central Nervous System. Cells 2021;10:2191. [PMID: 34571840 DOI: 10.3390/cells10092191] [Reference Citation Analysis]
288 Lee JW, Kim N, Nam RH, Lee SM, Kwon YH, Sohn SD, Kim JM, Lee DH, Jung HC. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance. Helicobacter. 2019;24:e12561. [PMID: 30632237 DOI: 10.1111/hel.12561] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 9.7] [Reference Citation Analysis]
289 Dargiene G, Kupcinskas J, Jonaitis L, Vezbavicius M, Kadusevicius E, Kupcinskiene E, Frandsen TH, Kucinskiene R, Kupcinskas L, Andersen LP. Primary antibiotic resistance of Helicobacter pylori strains among adults and children in a tertiary referral centre in Lithuania. APMIS 2018;126:21-8. [DOI: 10.1111/apm.12752] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
290 Dong SQ, Singh TP, Wei X, Yao H, Wang HL. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion? Helicobacter 2017;22:e12438. [DOI: 10.1111/hel.12438] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
291 Uddin R, Khalil W. A comparative proteomic approach using metabolic pathways for the identification of potential drug targets against Helicobacter pylori. Genes Genomics 2020;42:519-41. [PMID: 32193857 DOI: 10.1007/s13258-020-00921-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
292 Hamza D, Elhelw R, Elhariri M, Ragab E. Genotyping and antimicrobial resistance patterns of Helicobacter pylori in human and dogs associated with A2142G and A2143G point mutations in clarithromycin resistance. Microbial Pathogenesis 2018;123:330-8. [DOI: 10.1016/j.micpath.2018.07.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
293 Muñoz N, Sánchez-Delgado J, Baylina M, López-Góngora S, Calvet X. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. Gastroenterol Hepatol 2018;41:654-62. [PMID: 30180998 DOI: 10.1016/j.gastrohep.2018.06.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
294 Fiorini G, Zullo A, Saracino IM, Gatta L, Pavoni M, Vaira D. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice. Eur J Gastroenterol Hepatol. 2018;30:621-625. [PMID: 29481383 DOI: 10.1097/meg.0000000000001102] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
295 Eslami M, Yousefi B, Kokhaei P, Jazayeri Moghadas A, Sadighi Moghadam B, Arabkari V, Niazi Z. Are probiotics useful for therapy of Helicobacter pylori diseases? Comparative Immunology, Microbiology and Infectious Diseases 2019;64:99-108. [DOI: 10.1016/j.cimid.2019.02.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
296 Papastergiou V, Mathou N, Licousi S, Evgenidi A, Paraskeva KD, Giannakopoulos A, Stavrou PZ, Platsouka E, Karagiannis JA. Seven-day genotypic resistance-guided triple Helicobacter pylori eradication therapy can be highly effective. Ann Gastroenterol 2018;31:198-204. [PMID: 29507466 DOI: 10.20524/aog.2017.0219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
297 Livzan MA. [Underwater rocks of anti - helicobacter therapy]. Ter Arkh 2019;91:141-7. [PMID: 32598766 DOI: 10.26442/00403660.2019.08.000386] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
298 Gao CP, Xiao X, Liu PX, Zhou Z, Li LP, Han SX. High-dose amoxicillin/esomeprazole dual therapy as a first-line therapy for Helicobacter pylori eradication. Shijie Huaren Xiaohua Zazhi 2018; 26(6): 353-359 [DOI: 10.11569/wcjd.v26.i6.353] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
299 Mori H, Suzuki H, Matsuzaki J, Masaoka T, Kanai T. Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimens. United European Gastroenterol J. 2018;6:391-397. [PMID: 29774152 DOI: 10.1177/2050640617737215] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
300 Nkuize M, Vanderpas J, Buset M, Gomez-Galdon M, Delforge M, Miendje-Deyi VY, Muls V, De Wit S. Primary antibiotic resistance of Helicobacter pylori isolates is twofold more frequent in HIV-positive than HIV-negative individuals: A descriptive observational study. Microbiologyopen 2021;10:e1184. [PMID: 34180600 DOI: 10.1002/mbo3.1184] [Reference Citation Analysis]
301 Duan F, Song C, Zhang J, Wang P, Ye H, Dai L, Wang K. Evaluation of the Epidemiologic Efficacy of Eradicating Helicobacter pylori on Development of Gastric Cancer. Epidemiol Rev. 2019;41:97-108. [PMID: 31497856 DOI: 10.1093/epirev/mxz006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
302 Fong P, Hao CH, Io CC, Sin PI, Meng LR. In Silico and In Vitro Anti-Helicobacter Pylori Effects of Combinations of Phytochemicals and Antibiotics. Molecules 2019;24:E3608. [PMID: 31591315 DOI: 10.3390/molecules24193608] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
303 Gong EJ, Ahn JY, Kim JM, Lee SM, Na HK, Lee JH, Jung KW, Choi KD, Kim DH, Song HJ, Lee GH, Kim SW, Jung HY. Genotypic and Phenotypic Resistance to Clarithromycin in Helicobacter pylori Strains. J Clin Med 2020;9:E1930. [PMID: 32575584 DOI: 10.3390/jcm9061930] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
304 Hu Y, Wan JH, Li XY, Zhu Y, Graham DY, Lu NH. Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori. Aliment Pharmacol Ther. 2017;46:773-779. [PMID: 28892184 DOI: 10.1111/apt.14319] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
305 Luo P, Huang Y, Hang X, Tong Q, Zeng L, Jia J, Zhang G, Bi H. Dihydrotanshinone I Is Effective against Drug-Resistant Helicobacter pylori In Vitro and In Vivo. Antimicrob Agents Chemother 2021;65:e01921-20. [PMID: 33318002 DOI: 10.1128/AAC.01921-20] [Reference Citation Analysis]
306 Salehi N, Attaran B, Eskini N, Esmaeili M, Sharifirad A, Sadeghi M, Mohammadi M. New insights into resistance of Helicobacter pylori against third‐ and fourth‐generation fluoroquinolones: A molecular docking study of prevalent GyrA mutations. Helicobacter 2019;24. [DOI: 10.1111/hel.12628] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
307 Yu X, Feng D, Wang G, Dong Z, Zhou Q, Zhang Y. Correlation Analysis of Helicobacter pylori Infection and Digestive Tract Symptoms in Children and Related Factors of Infection. Iran J Public Health 2020;49:1912-20. [PMID: 33346225 DOI: 10.18502/ijph.v49i10.4694] [Reference Citation Analysis]
308 [DOI: 10.1101/569814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
309 Urrutia-Baca VH, Gomez-Flores R, De La Garza-Ramos MA, Tamez-Guerra P, Lucio-Sauceda DG, Rodríguez-Padilla MC. Immunoinformatics Approach to Design a Novel Epitope-Based Oral Vaccine Against Helicobacter pylori. J Comput Biol 2019;26:1177-90. [PMID: 31120321 DOI: 10.1089/cmb.2019.0062] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
310 Bhattacharjee S, Mejías-luque R, Loffredo-verde E, Toska A, Flossdorf M, Gerhard M, Prazeres da Costa C. Concomitant Infection of S. mansoni and H. pylori Promotes Promiscuity of Antigen-Experienced Cells and Primes the Liver for a Lower Fibrotic Response. Cell Reports 2019;28:231-244.e5. [DOI: 10.1016/j.celrep.2019.05.108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
311 Shakoor S, Platts-mills JA, Hasan R. Antibiotic-Resistant Enteric Infections. Infectious Disease Clinics of North America 2019;33:1105-23. [DOI: 10.1016/j.idc.2019.05.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
312 Alba C, Blanco A, Alarcón T. Antibiotic resistance in Helicobacter pylori. Curr Opin Infect Dis 2017;30:489-97. [PMID: 28704226 DOI: 10.1097/QCO.0000000000000396] [Cited by in Crossref: 71] [Cited by in F6Publishing: 34] [Article Influence: 17.8] [Reference Citation Analysis]
313 Marques B, Donato MM, Cardoso O, Luxo C, Martinho A, Almeida N. Study of rdxA and frxA genes mutations in metronidazole-resistant and -susceptible Helicobacter pylori clinical isolates from the central region of Portugal. J Glob Antimicrob Resist 2019;17:300-4. [PMID: 30658199 DOI: 10.1016/j.jgar.2019.01.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
314 Lyu QJ, Pu QH, Zhong XF, Zhang J. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials. Biomed Res Int 2019;2019:9781212. [PMID: 31211144 DOI: 10.1155/2019/9781212] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]